ABCB1 rs1045643: Understanding This Pharmacogenomic Variant
The rs1045643 variant is a single nucleotide polymorphism located within the ABCB1 gene, which encodes the P-glycoprotein efflux transporter. This variant is frequently studied in pharmacogenomics due to its potential influence on how the body processes various medications.
What each genotype means
Typical P-glycoprotein expression
This genotype is associated with standard expression levels of the P-glycoprotein transporter. Research suggests individuals with this profile may experience higher drug efflux activity compared to those with the T allele, which can influence the plasma levels of certain medications like carbamazepine. Because evidence regarding clinical outcomes remains limited and mixed, you should discuss any concerns about medication efficacy or dosing with your clinician or pharmacist.
This is a common genotype, particularly in populations of African ancestry, and is found at varying frequencies globally.
Intermediate transporter activity
This genotype represents a heterozygous state that may result in intermediate P-glycoprotein transporter activity. Studies have explored whether this variation influences how the body processes drugs like anticonvulsants or statins, though findings are often inconsistent across different clinical trials. Please consult your healthcare provider or pharmacist to determine if this genetic information is relevant to your specific medication regimen.
This genotype is frequently observed across most global populations, representing a significant portion of the population in many regions.
Altered transporter function
This genotype is associated with potential changes in the structure and function of the P-glycoprotein transporter, which may affect how certain drugs are transported or metabolized. Some research has investigated links between this genotype and altered responses to medications like carbamazepine or an increased risk of statin-associated muscle symptoms, but the evidence is not definitive and remains a subject of ongoing study. Always discuss your medication response and any side effects with your doctor or pharmacist before making changes to your treatment.
This genotype is common in individuals of European ancestry and is generally less frequent in populations of African ancestry.
What is the rs1045643 Variant?
The rs1045643 variant is a specific change in the DNA sequence of the ABCB1 gene. In genetics, a single nucleotide polymorphism, or SNP, represents a variation at a single position in the DNA chain. This particular variant is often discussed in the context of the ABCB1 gene, which provides instructions for making a protein called P-glycoprotein. P-glycoprotein acts as a biological pump, moving various substances, including many pharmaceutical drugs, across cell membranes. Because this pump is found in critical barriers throughout the body—such as the blood-brain barrier, the lining of the intestines, and the kidneys—variations in the gene that encodes it may theoretically alter how much of a drug enters the bloodstream or reaches specific tissues. Researchers track these variants to understand if they contribute to differences in how individuals respond to medical treatments.
The Role of the ABCB1 Gene
The ABCB1 gene, also known as the multidrug resistance 1 (MDR1) gene, is responsible for producing P-glycoprotein. This protein is an ATP-dependent efflux transporter, meaning it uses energy to push molecules out of cells. By doing so, P-glycoprotein serves a protective role, limiting the absorption of toxins from the gut and preventing harmful substances from accumulating in sensitive tissues like the brain. Because many medications are substrates for this pump, the efficiency of P-glycoprotein can influence the pharmacokinetics—the absorption, distribution, metabolism, and excretion—of those drugs. When the expression or activity of this transporter is altered, it may lead to variations in drug concentration within the body. Understanding the function of this gene is a cornerstone of pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs.
Research and Evidence Strength
Scientific research into rs1045643 has explored its potential impact on drug response, but the evidence remains limited and often inconsistent. While some studies have suggested that variants in ABCB1 might correlate with altered P-glycoprotein expression or activity, meta-analyses have frequently found that these associations are small or not statistically significant across diverse clinical populations. For instance, studies investigating the role of ABCB1 variants in antidepressant treatment outcomes have often failed to find a clear, actionable link that would support routine clinical testing. The complexity of drug response, which is influenced by many genes, environmental factors, and lifestyle choices, makes it difficult to isolate the effect of a single SNP. Consequently, current scientific consensus does not support the use of this specific variant to guide clinical dosing decisions at this time.
What You Can and Cannot Do With This Information
It is important to understand that genetic information regarding rs1045643 is for educational purposes and does not constitute medical advice. You cannot use this information to diagnose a condition, predict a specific drug reaction, or alter your medication regimen. Because the evidence linking this variant to clinical outcomes is limited and mixed, it is not currently used in standard clinical practice to personalize drug therapy. If you have questions about how your medications are working or if you are experiencing side effects, the most appropriate step is to consult with your healthcare provider or a pharmacist. They are equipped to evaluate your entire health profile, including other medications you may be taking, to ensure your treatment plan is safe and effective. Never stop or change the dosage of a prescribed medication based on genetic test results without professional medical guidance.
How common is this variant?
The frequency of the rs1045643 variant varies significantly by ancestry. The minor allele frequency is approximately 0.40–0.50 in European populations and ranges from 0.10–0.15 in African populations.
Frequently asked questions
Is rs1045643 used to predict drug side effects?
Currently, rs1045643 is not used in clinical practice to predict drug side effects. While it is a subject of research, the evidence linking it to specific clinical outcomes is not strong enough to guide medical treatment.
Should I get tested for ABCB1 variants?
There is no standard medical recommendation to get tested for this specific ABCB1 variant. Because the clinical utility is not established, such testing is generally not considered useful for making healthcare decisions.
Does this variant mean I am resistant to medication?
No, having a specific genotype for rs1045643 does not mean you are resistant to medication. Drug response is a complex process influenced by many factors, and this single variant is not a reliable predictor of how you will respond to any specific drug.
Where can I find more information on pharmacogenomics?
You can find reliable information on pharmacogenomics through resources like PharmGKB, the NIH's MedlinePlus Genetics, and the Clinical Pharmacogenetics Implementation Consortium (CPIC). These organizations provide evidence-based summaries regarding the intersection of genetics and drug therapy.
Sources & further reading
Educational information only, last refreshed 9/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1045643?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ABCB1
This variant is studied for its influence on the pharmacokinetics of immunosuppressive drugs like cyclosporine and tacrolimus in transplant patients.
Nonsynonymous variant in ABCB1 altering P-glycoprotein transporter kinetics.
A variant associated with potential differences in drug absorption and clinical outcomes in patients undergoing specific pharmacological therapies.
This SNP is linked to variations in the pharmacokinetics of drugs that are substrates for the ABCB1 transporter protein.
Synonymous exon 26 variant in ABCB1 linked to altered mRNA stability and variable response to multiple cardiovascular medications.
Synonymous polymorphism in the ABCB1 (MDR1) transporter gene influencing substrate drug efflux and systemic drug exposure.